Collective Audience And 3 Other Stocks Under $1 Insiders Are Buying

The Dow Jones index closed lower by around 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

OPKO Health

• The Trade: OPKO Health, Inc. OPK Vice Chairman and CTO PH Jane Hsiao acquired a total of 150,000 shares an average price of $0.95. To acquire these shares, it cost around $142,500.
• What’s Happening: OPKO Health recently priced private offering of $200 million convertible senior notes due 2029.
• What OPKO Health Does: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs.

BioCorRx

• The Trade: BioCorRx Inc. BICX Interim President Louis C Lucido acquired a total of 3,126 shares at at an average price of $0.70. To acquire these shares, it cost around $2,188.
• What’s Happening: The company’s stock fell around 22% over the past month.
• What BioCorRx Does: BioCorRx Inc through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders.

Check This Out: Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive'

Coeptis Therapeutics

• The Trade: Coeptis Therapeutics Holdings, Inc. COEP CFO Brian Cogley acquired a total of 5,000 shares at an average price of $0.67. The insider spent around $3,350 to buy those shares.
• What’s Happening: Coeptis Therapeutics recently said that Dave Mehalick, President and CEO, issued a Letter to Shareholders providing a review of its 2023 achievements and anticipated milestones for 2024.
• What Coeptis Therapeutics Does: Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer.

Collective Audience

• The Trade: Collective Audience, Inc. CAUD CEO Peter Bordes acquired a total of 20,000 shares at an average price of $0.94. The insider spent around $18,800 to buy those shares.
• What’s Happening: Collective Audience named former Ogilvy and WPP executive, Christopher Andrews, as Chief Operating Officer.
• What Collective Audience Does: Collective Audience Inc is a provider of e-commerce and digital customer acquisition solutions by simplifying digital advertising.

Don’t forget to check out our premarket coverage here